ArticleHepatology forum2026
Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/immunosuppressive therapy.
Article in Hepatology forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: This study aimed to determine the efficacy and safety of tenofovir alafenamide fumarate (TAF) prophylaxis in hepatitis B virus (HBV)-infected or HBV-experienced individuals with benign and malignant diseases receiving chemo/immunosuppressive or biological modifier therapy. Materials and Methods: This is a multicenter, observational study in which data from 13 centers were reviewed and entered into a standardized electronic case report form. Results: A total of 158 individuals who received TAF prophylaxis were included in the analysis. Before starting the prophylaxis, 51 individuals were hepatitis B surface antigen positive, while 107 were HBV-experienced. Thirty patients had detectable HBV DNA levels. Twelve of them had abnormal serum alanine aminotransferase levels. Forty patients were switched to TAF. Solid tumors (34%) were the most common primary disease types. The median follow-up period was 17.2 months. From baseline to the end of the follow-up period, none of the patients had clinical, biochemical, or serological evidence of HBV reactivation under TAF prophylaxis. The virological response rate was 87%. HBV suppression was well maintained after switching in the 40 patients who were switched to TAF treatment. All patients maintained their chemo/immunosuppressive therapy without interruption. TAF prophylaxis was well tolerated. No drug discontinuation due to adverse effects was observed. No HBV-related morbidity or mortality was observed during the TAF prophylaxis. No significant differences were found in the glomerular filtration rate change or hypophosphatemia during TAF prophylaxis, but the serum triglyceride levels were significantly increased (p=0.019). Conclusion: TAF prophylaxis is effective, safe, and tolerable in preventing chemo/immunosuppressive or biological modifier-induced HBV reactivation in HBV-infected or HBV-experienced individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.